Uygur Safak, Eryilmaz Tolga, Bulam Hakan, Yavuzer Reha, Latifoglu Osman
Department of Plastic, Reconstructive and Aesthetic Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey.
J Craniofac Surg. 2013 Jul;24(4):1285-7. doi: 10.1097/SCS.0b013e318292c80c.
Botulinum toxin type A (BTX-A) is currently used in temporal brow lifting. Reducing the activity of the superolateral portion of orbicularis oculi muscle causes lateral brow elevation. The objective of this study was to determine the quantitative brow elevation after paralysis of the superolateral portion of orbicularis oculi muscle.
This study includes 10 female patients. Six units of BTX-A were injected into the superolateral portion of the orbicularis oculi in a serial manner into 3 points, below the lateral half of the brow at each side. Bilateral measurements were obtained by using calipers, immediately before and 2 weeks after the treatment. The medial canthus to the medial brow margin (AB), the lateral brow margin to the lateral canthus (CD), the medial brow margin to the lateral brow margin (BC), the brow apex to upper lid margin at the level of the lateral limbus (EF), the brow apex to the medial brow margin (EB), the brow apex to the lateral brow margin (EC), and upper eyelid margin to lower eyelid margin at the level of the pupil (GH), were measured.
There were no statistically significant differences found between pretreatment and posttreatment left and right measurements. There were statistically significant increases in CD, EF, and GH measurements, which are point out brow elevation. There were no statistically significant differences found in other measurements.
Same doses of BTX-A application did not disrupt symmetry. Applications of 6U BTX-A to the superolateral portion of orbicularis oculi provide brow elevation and increased interpalbebral distance and upper eyelid distance. Our study has confirmed that BTX-A treatment of superolateral portion of the orbicularis oculi muscle produces quantitative temporal brow elevation.
A型肉毒杆菌毒素（BTX-A）目前用于颞部提眉。降低眼轮匝肌上外侧部分的活性可导致眉外侧抬高。本研究的目的是确定眼轮匝肌上外侧部分麻痹后的定量眉抬高情况。
本研究包括10名女性患者。将6单位的BTX-A以连续方式注射到每侧眉外侧半下方眼轮匝肌的上外侧部分的3个点。在治疗前和治疗后2周立即使用卡尺进行双侧测量。测量了内眦至眉内侧缘（AB）、眉外侧缘至外眦（CD）、眉内侧缘至眉外侧缘（BC）、眉尖至外眦角水平的上睑缘（EF）、眉尖至眉内侧缘（EB）、眉尖至眉外侧缘（EC）以及瞳孔水平的上睑缘至下睑缘（GH）。
治疗前和治疗后左右测量值之间未发现统计学上的显著差异。CD、EF和GH测量值有统计学上的显著增加，这表明眉抬高。其他测量值未发现统计学上的显著差异。
相同剂量的BTX-A应用并未破坏对称性。将6U BTX-A应用于眼轮匝肌上外侧部分可使眉抬高，并增加睑裂间距和上睑间距。我们的研究证实，BTX-A治疗眼轮匝肌上外侧部分可产生定量的颞部眉抬高。
